Shareholders of verona pharma approve proposed acquisition by merck

London, u.k., and raleigh, n.c., sept. 24, 2025 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on july 8, 2025 relating to its proposed acquisition by merck & co., inc. (nyse: mrk) (“merck”) through a wholly owned subsidiary or a nominee, today announced that its shareholders have approved the proposal for merck to acquire verona pharma for $107 per american depository share (ads), each of which represents eight verona pharma ordinary shares, for a total transaction value of approximately $10 billion (the “transaction”).
VRNA Ratings Summary
VRNA Quant Ranking